Research location
Mostar
Bosnia and Herzegovina
Advertisement
Research activity in Mostar
Bosnia and HerzegovinaCureCurrent currently publishes aggregate city-level research activity for this location: 32 trials and 34 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mostar
32 linked trials · page 1 of 1A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerNCT07130916 · 2024-12-05 · 1 site observation
RECRUITING
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEFNCT07417215 · 2026-01-30 · 1 site observation
COMPLETED
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 · 2025-07-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerNCT06348199 · 2024-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast CancerNCT05622058 · 2023-01-09 · 1 site observation
TERMINATED
Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart FailureNCT05747820 · 2022-09-28 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 · 2022-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 1 site observation
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 2 site observations
TERMINATED
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)NCT04712669 · 2021-03-15 · 1 site observation
COMPLETED
Relationship of Reduced Arterial Stiffness and Hs-CRP With GDM.NCT05479565 · 2020-09-01 · 1 site observation
COMPLETED
MTHFR Mutation and Concentration of B12,Folic Acid,Homocysteine and HS CRP in the Blood of Pregnant Women With GDM.NCT04952324 · 2020-09-01 · 2 site observations
COMPLETED
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)NCT04338022 · 2020-06-12 · 1 site observation
TERMINATED
NATriuretic Response to Expansion and dIUretics in huMans With Heart FailureNCT04235062 · 2020-04-01 · 1 site observation
COMPLETED
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisNCT03523858 · 2018-05-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSNCT03290131 · 2018-01-28 · 1 site observation
COMPLETED
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisNCT02647762 · 2017-10-30 · 1 site observation
TERMINATED
Study of an Anti-TLR4 mAb in Rheumatoid ArthritisNCT03241108 · 2017-05-10 · 1 site observation
COMPLETED
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLCNCT04633564 · 2017-01-21 · 1 site observation
COMPLETED
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid ArthritisNCT02819726 · 2016-10-11 · 1 site observation
COMPLETED
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerNCT02810457 · 2016-09-07 · 1 site observation
COMPLETED
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsNCT02111564 · 2014-01-07 · 1 site observation
COMPLETED
MabionCD20® Compared to MabThera® in Patients With Rheumatoid ArthritisNCT02468791 · 2013-05-01 · 1 site observation
COMPLETED
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCNCT01798485 · 2013-04-01 · 1 site observation
TERMINATED
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01707992 · 2013-02-20 · 1 site observation
COMPLETED
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT01578785 · 2012-03-01 · 1 site observation
TERMINATED
Long Term Extension Study For SPM-005 ParticipantsNCT01552538 · 2012-01-01 · 1 site observation
UNKNOWN
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid ArthritisNCT01552941 · 2011-07-01 · 1 site observation
COMPLETED
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung CancerNCT01348126 · 2011-05-01 · 1 site observation
TERMINATED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast CancerNCT00077857 · 2003-07-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.